GLP-1 Drugs and Surgery Cut Fat and Muscle
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Vanderbilt University Medical Center researchers analyzed 1,257 bariatric surgery patients and 1,809 patients on semaglutide or tirzepatide, finding both treatments produced substantial fat loss alongside modest reductions in fat-free mass over 24 months.
- The study, published in JAMA Network Open, found the ratio of fat-free mass to fat mass improved under both treatments, signaling an overall healthier body composition despite the muscle loss.
- Male patients preserved fat-free mass more effectively over the long term than female patients, a gender difference the researchers flagged as warranting further investigation.
- The tradeoff matters clinically because higher fat mass is linked to greater cardiovascular death risk while higher fat-free mass is linked to lower mortality — meaning the modest muscle loss tempers, but does not erase, the health benefits.
- The retrospective analysis, led by Danxia Yu, PhD, and Jason Samuels, MD, used bioelectrical impedance analysis on electronic health records and excluded patients with end-stage renal disease or congestive heart failure.
- The researchers called for more studies in real-world clinical settings to clarify how fat and lean mass shift with each treatment, as current evidence is still evolving.
Why it matters: Clinicians prescribing GLP-1 drugs or recommending bariatric surgery have long focused on the scale, but this 3,066-patient Vanderbilt study shows the same modest muscle loss occurs regardless of method — a concern for the millions of patients using semaglutide or tirzepatide, who may need resistance training or protein-targeted strategies to protect lean mass and the survival benefit it confers.
